Skip to content

Exploration of a whole-process, ward-based clinical pharmacist service model for constructing a DRGs-based clinical pathway of drug therapy for COPD patients.

Exploration of a whole-process, ward-based clinical pharmacist service model for constructing a DRGs-based clinical pathway of drug therapy for COPD patients.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126034
Enrollment
Unknown
Registered
2026-06-02
Start date
2026-06-02
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Control group:None
Experimental group:Construct a pharmacotherapy clinical pathway to assist clinicians in formulating medication plans and provide inpatient pharmaceutical care.

Sponsors

Ankang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Chronic obstructive pulmonary disease (COPD): meets the diagnostic criteria defined by the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2.COPD inpatients aged =18 years (inclusive, based on the date of informed consent). 3.Medical insurance patients classified under health insurance as chronic obstructive airway disease were enrolled as study subjects, with the DRG groups being: chronic obstructive airway disease with complications or comorbidities, and chronic obstructive airway disease without complications or comorbidities. 4.Subjects who fully understand the study's purpose, nature, methods, and possible adverse reactions, and voluntarily provide written informed consent.

Exclusion criteria

Exclusion criteria: 1.Having participated in another drug clinical study within 3 months before the start of this study. 2.Being pregnant or lactating; 3.Any other situation that, in the judgment of the investigator, may compromise the subject's ability to provide informed consent or comply with the study protocol, or could affect the study results or the subject's safety if enrolled.

Design outcomes

Primary

MeasureTime frame
Average surplus amount per case for COPD-related DRG groups;

Secondary

MeasureTime frame
Average total medical cost per case;Average length of hospital stay (ALOS);Average drug cost per case and drug cost ratio (proportion of drug expenses);Antibacterial drug cost ratio (proportion of antibacterial drug costs);Use ratio of key monitored drugs (proportion of key monitored drug costs);Incidence of irrational drug use;

Countries

China

Contacts

Public ContactLI Yuxiu

Ankang People's Hospital

892374440@qq.com+86 915 3368320

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026